Immunome (NASDAQ:IMNM) Issues Quarterly Earnings Results

Immunome (NASDAQ:IMNM) released its earnings results on Wednesday. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16), Zacks reports. The company had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%.

Immunome Stock Performance

NASDAQ IMNM opened at $8.66 on Friday. The stock has a market cap of $690.87 million, a PE ratio of -1.07 and a beta of 1.93. Immunome has a fifty-two week low of $8.30 and a fifty-two week high of $26.70. The firm’s fifty day moving average price is $9.80 and its two-hundred day moving average price is $11.62.

Analysts Set New Price Targets

A number of research firms recently commented on IMNM. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Thursday. Guggenheim dropped their target price on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday. Stephens reiterated an “overweight” rating and set a $30.00 price target on shares of Immunome in a research report on Thursday. Finally, Lifesci Capital initiated coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $25.50.

Insiders Place Their Bets

In other news, CEO Clay B. Siegall purchased 150,000 shares of Immunome stock in a transaction dated Friday, January 31st. The shares were bought at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.60% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.